<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36001182</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1534-4681</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of surgical oncology</Title><ISOAbbreviation>Ann Surg Oncol</ISOAbbreviation></Journal><ArticleTitle>ASO Visual Abstract: Male Breast Cancer Patients and Surgeon Experience: The Male WhySurg Study.</ArticleTitle><Pagination><StartPage>6132</StartPage><MedlinePgn>6132</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-022-12218-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chichura</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Pritzker School of Medicine at University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attai</LastName><ForeName>Deanna J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuchta</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Kyra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Pritzker School of Medicine at University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopkash</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Pritzker School of Medicine at University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pesce</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Pritzker School of Medicine at University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA. kyao@northshore.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Pritzker School of Medicine at University of Chicago, Chicago, IL, USA. kyao@northshore.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg Oncol</MedlineTA><NlmUniqueID>9420840</NlmUniqueID><ISSNLinking>1068-9265</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="Y">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066231" MajorTopicYN="Y">Surgeons</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>24</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36001182</ArticleId><ArticleId IdType="doi">10.1245/s10434-022-12218-4</ArticleId><ArticleId IdType="pii">10.1245/s10434-022-12218-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35985745</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>First report of bilateral synchronous male accessory breast cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e250927</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2022-250927</ELocationID><Abstract><AbstractText>Accessory breast occurs due to the persistence of milk line in the non-thoracic region. Malignant transformation in male accessory breast is very rare, with 16 reports documented across the world. No bilateral synchronous accessory male breast cancer has been reported. We present the first case reported globally of a man in his 70s with a complaint of left axillary lump and chronic rash for 3 years. About 1&#x2009;year ago, additional reddish rash was detected in the right axilla. Initial skin biopsy from a private hospital confirmed mammary carcinoma with skin invasion. Subsequent left breast mastectomy with left axillary lymph node dissection and right wide excision was performed. Final pathological result was grade 2 invasive ductal carcinoma in the left accessory breast and Paget's disease in the contralateral axilla. Postoperative treatment of adjuvant paclitaxel and trastuzumab was prescribed, which was followed by adjuvant radiation therapy.</AbstractText><CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lerttiendamrong</LastName><ForeName>Bhoowit</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0143-6407</Identifier><AffiliationInfo><Affiliation>Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vongsaisuwon</LastName><ForeName>Mawin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand mawin.v@chula.ac.th.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001941" MajorTopicYN="Y">Breast Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="Y">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="Y">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005076" MajorTopicYN="Y">Exanthema</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Breast surgery</Keyword><Keyword MajorTopicYN="N">General surgery</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35985745</ArticleId><ArticleId IdType="pmc">PMC9396125</ArticleId><ArticleId IdType="doi">10.1136/bcr-2022-250927</ArticleId><ArticleId IdType="pii">15/8/e250927</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Korde LA, Zujewski JA, Kamin L, et al. . Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010;28:2114&#x2013;22. 10.1200/JCO.2009.25.5729</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.25.5729</ArticleId><ArticleId IdType="pmc">PMC2860409</ArticleId><ArticleId IdType="pubmed">20308661</ArticleId></ArticleIdList></Reference><Reference><Citation>Burga AM, Fadare O, Lininger RA, et al. . Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 2006;449:507&#x2013;12. 10.1007/s00428-006-0305-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00428-006-0305-3</ArticleId><ArticleId IdType="pmc">PMC1888721</ArticleId><ArticleId IdType="pubmed">17058095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M, Li D, Su Y, et al. . Male axillary accessory breast cancer: a case report. Medicine 2020;99:e19506. 10.1097/MD.0000000000019506</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000019506</ArticleId><ArticleId IdType="pmc">PMC7440245</ArticleId><ArticleId IdType="pubmed">32176095</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang L, Cui M, Dai W, et al. . Diagnosis and treatment of male accessory breast cancer: a comprehensive systematic review. Front Oncol 2021;11:640000. 10.3389/fonc.2021.640000</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.640000</ArticleId><ArticleId IdType="pmc">PMC8039378</ArticleId><ArticleId IdType="pubmed">33854973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 2013;24:1434&#x2013;43. 10.1093/annonc/mdt025</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdt025</ArticleId><ArticleId IdType="pubmed">23425944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngoo KS, Rohaizak M, Naqiyah I, et al. . Male breast cancer: experience from a Malaysian tertiary centre. Singapore Med J 2009;50:519&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">19495524</ArticleId></ArticleIdList></Reference><Reference><Citation>Satram-Hoang S, Moran EM, Anton-Culver H, et al. . A pilot study of male breast cancer in the Veterans Affairs healthcare system. J Environ Pathol Toxicol Oncol 2010;29:235&#x2013;44. 10.1615/JEnvironPatholToxicolOncol.v29.i3.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/JEnvironPatholToxicolOncol.v29.i3.60</ArticleId><ArticleId IdType="pubmed">21303329</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert SF, Soliman AS, Karkouri M, et al. . Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. Breast Dis 2011;33:17&#x2013;26. 10.3233/BD-2010-0323</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/BD-2010-0323</ArticleId><ArticleId IdType="pmc">PMC4276136</ArticleId><ArticleId IdType="pubmed">22142662</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard BA, Gusterson BA. Human breast development. J Mammary Gland Biol Neoplasia 2000;5:119&#x2013;37. 10.1023/A:1026487120779</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1026487120779</ArticleId><ArticleId IdType="pubmed">11149569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao J-Y, Yang C-C, Liu F-F, et al. . Accessory breast cancer occurring concurrently with bilateral primary invasive breast carcinomas: a report of two cases and literature review. Cancer Biol Med 2012;9:197&#x2013;201. 10.7497/j.issn.2095-3941.2012.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.7497/j.issn.2095-3941.2012.03.008</ArticleId><ArticleId IdType="pmc">PMC3643663</ArticleId><ArticleId IdType="pubmed">23691479</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak S, Preston J. A rare case of multiple accessory breast tissue in the axillae, lower abdomen and vulval areas. J Obstet Gynaecol 2007;27:531&#x2013;3. 10.1080/01443610701467473</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01443610701467473</ArticleId><ArticleId IdType="pubmed">17701815</ArticleId></ArticleIdList></Reference><Reference><Citation>Thasanabanchong P, Vongsaisuwon M. Unexpected presentation of accessory breast cancer presenting as a subcutaneous mass at costal ridge: a case report. J Med Case Rep 2020;14:45. 10.1186/s13256-020-02366-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-020-02366-0</ArticleId><ArticleId IdType="pmc">PMC7110727</ArticleId><ArticleId IdType="pubmed">32234067</ArticleId></ArticleIdList></Reference><Reference><Citation>Visconti G, Eltahir Y, Van Ginkel RJ, et al. . Approach and management of primary ectopic breast carcinoma in the axilla: where are we? A comprehensive historical literature review. J Plast Reconstr Aesthet Surg 2011;64:e1&#x2013;11. 10.1016/j.bjps.2010.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2010.08.015</ArticleId><ArticleId IdType="pubmed">20934398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellon JR, Guo H, Barry WT, et al. . Local-Regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat 2019;176:303&#x2013;10. 10.1007/s10549-019-05238-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-019-05238-4</ArticleId><ArticleId IdType="pubmed">31004299</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams SJ, Kanthan R. Paget's disease of the male breast in the 21st century: a systematic review. Breast 2016;29:14&#x2013;23. 10.1016/j.breast.2016.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.breast.2016.06.015</ArticleId><ArticleId IdType="pubmed">27394005</ArticleId></ArticleIdList></Reference><Reference><Citation>Serour F, Birkenfeld S, Amsterdam E, et al. . Paget's disease of the male breast. Cancer 1988;62:601&#x2013;5. 10.1002/1097-0142(19880801)62:3&lt;601::AID-CNCR2820620326&gt;3.0.CO;2-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(19880801)62:3&lt;601::AID-CNCR2820620326&gt;3.0.CO;2-7</ArticleId><ArticleId IdType="pubmed">2839285</ArticleId></ArticleIdList></Reference><Reference><Citation>Salih AM, Hammood ZD, Kakamad FH, et al. . Paget's disease of the breast in male with underlying invasive ductal carcinoma: a case report with review of literature. Ann Med Surg 2021;72:103035. 10.1016/j.amsu.2021.103035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2021.103035</ArticleId><ArticleId IdType="pmc">PMC8599100</ArticleId><ArticleId IdType="pubmed">34820122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes S, Vide J, Moreira E, et al. . Paget disease of the male breast. Dermatol Online J 2017;23. 10.5070/D3234034642. [Epub ahead of print: 15 Apr 2017].</Citation><ArticleIdList><ArticleId IdType="doi">10.5070/D3234034642</ArticleId><ArticleId IdType="pubmed">28541881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YJ, Shin J, Jung J-M, et al. . Bilateral metachronous Paget's disease of the accessory breasts in a male. J Breast Cancer 2020;23:665&#x2013;71. 10.4048/jbc.2020.23.e38</Citation><ArticleIdList><ArticleId IdType="doi">10.4048/jbc.2020.23.e38</ArticleId><ArticleId IdType="pmc">PMC7779722</ArticleId><ArticleId IdType="pubmed">33408892</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35775632</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2354</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European journal of cancer care</Title><ISOAbbreviation>Eur J Cancer Care (Engl)</ISOAbbreviation></Journal><ArticleTitle>Response to "Re: 'Occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications-A qualitative study'".</ArticleTitle><Pagination><StartPage>e13646</StartPage><MedlinePgn>e13646</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ecc.13646</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hiltrop</LastName><ForeName>Kati</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8357-0855</Identifier><AffiliationInfo><Affiliation>Center for Health Communication and Health Services Research (CHSR), Department for Psychosomatic Medicine and Psychotherapy, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer Care (Engl)</MedlineTA><NlmUniqueID>9301979</NlmUniqueID><ISSNLinking>0961-5423</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Eur J Cancer Care (Engl). 2022 Jul;31(4):e13585</RefSource><PMID Version="1">35385181</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="Y">Breast Neoplasms, Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062707" MajorTopicYN="N">Return to Work</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35775632</ArticleId><ArticleId IdType="doi">10.1111/ecc.13646</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>da Silva, T. L. (2016). Male breast cancer: Medical and psychological management in comparison to female breast cancer. A review. Cancer Treatment Communications, 7, 23-34. https://doi.org/10.1016/j.ctrc.2016.03.004</Citation></Reference><Reference><Citation>Flick, U. (2014). An introduction to qualitative research (Vol. 5). Sage.</Citation></Reference><Reference><Citation>Halbach, S. M., Midding, E., Ernstmann, N., W&#xfc;rstlein, R., Weber, R., Christmann, S., &amp; Kowalski, C. (2020). Male breast cancer patients' perspectives on their health care situation: A mixed-methods study. Breast Care, 15(1), 22-29. https://doi.org/10.1159/000501956</Citation></Reference><Reference><Citation>Hiltrop, K., &amp; Ernstmann, N. (2021). Response to &#x2018;response to &#x201c;occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications-A qualitative study.&#x201d;&#x2019;. European Journal of Cancer Care, 30(4), e13471. https://doi.org/10.1111/ecc.13471</Citation></Reference><Reference><Citation>Hiltrop, K., Heidkamp, P., Halbach, S., Brock-Midding, E., Kowalski, C., Holmberg, C., &amp; Ernstmann, N. (2021). Occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications-a qualitative study. European Journal of Cancer Care, 30(4), e13402. https://doi.org/10.1111/ecc.13402</Citation></Reference><Reference><Citation>Malterud, K., Siersma, V. D., &amp; Guassora, A. D. (2016). Sample size in qualitative interview studies: Guided by information power. Qualitative Health Research, 26(13), 1753-1760. https://doi.org/10.1177/1049732315617444</Citation></Reference><Reference><Citation>Midding, E., Halbach, S. M., Kowalski, C., Weber, R., W&#xfc;rstlein, R., &amp; Ernstmann, N. (2018). Men with a &#x201c;woman's disease&#x201d;: Stigmatization of male breast cancer patients-a mixed methods analysis. American Journal of Men's Health, 12(6), 2194-2207. https://doi.org/10.1177/1557988318799025</Citation></Reference><Reference><Citation>Midding, E., Halbach, S. M., Kowalski, C., Weber, R., W&#xfc;rstlein, R., &amp; Ernstmann, N. (2019). Social support of male breast cancer patients-A mixed-methods analysis. American Journal of Men's Health, 13(4), 1557988319870001. https://doi.org/10.1177/1557988319870001</Citation></Reference><Reference><Citation>Que, W.-Q., Li, J.-M., Tang, J., Zhao, J.-Y., Su, X.-Q., &amp; Guo, Y.-J. (2022). Re: 'occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications-a qualitative study. European Journal of Cancer Care, e13585. https://doi.org/10.1111/ecc.13585</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35473920</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-0666</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical breast cancer</Title><ISOAbbreviation>Clin Breast Cancer</ISOAbbreviation></Journal><ArticleTitle>Effect of Breast Conservation Therapy vs Mastectomy on Overall Survival and Breast Cancer-Specific Survival Among Men With Stage I-II Breast Cancer: Analysis of SEER, 2000-2018.</ArticleTitle><Pagination><StartPage>410</StartPage><EndPage>417</EndPage><MedlinePgn>410-417</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2022.03.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1526-8209(22)00069-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Male breast cancer is a rare malignant tumor, and outcomes of breast conservation therapy (BCT) are currently lacking.</AbstractText><AbstractText Label="METHOD">The retrospective, population-based cohort study included 1369 stage I-II (T1-2 N0-1 M0) male breast cancer patients from the SEER database (2000-2018). The patients were grouped in two groups: BCT group and mastectomy group, according to surgical and radiation therapy. Kaplan-Meier method and univariable Cox proportional hazard analysis were used to compare overall survival (OS) and breast cancer-specific survival (BCSS) between two treatment groups. Propensity score matching (PSM) was performed to balance the confounding factors.</AbstractText><AbstractText Label="RESULTS">Of the 1369 men, 97 (7%) patients received BCT, 1272 (93%) received mastectomy alone. The 5- and 10-year OS rates were 92.3% and 80.7% for BCT group compared with 80.4% and 61.4% for mastectomy group. The 5- and 10-year BCSS rates were 96.5% and 93.9% for patients undergoing BCT, as compared with 93.1% and 84.4% for patients undergoing mastectomy. Compared with mastectomy group, BCT group showed improved OS (hazard ratio [HR], 0.294; 95% CI 0.138-0.623, P&#xa0;=&#xa0;.002) and BCSS (hazard ratio [HR], 0.182; 95% CI 0.040-0.820, P&#xa0;=&#xa0;.027). Of the 791 patients with T1 stage, BCT showed insignificant association with OS (hazard ratio [HR], 0.555; 95% CI 0.207-1.488, P&#xa0;=&#xa0;.242) and BCSS (hazard ratio [HR], 1.217; 95% CI 0.171-8.675, P&#xa0;=&#xa0;.844).</AbstractText><AbstractText Label="CONCLUSION">The results of this cohort study suggest that BCT is at least equivalent to mastectomy in male breast cancer patients. The underlying mechanism of this association needs further research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yushuang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jierong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuelu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Zhenhai</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. Electronic address: mazhenhai@dmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Breast Cancer</MedlineTA><NlmUniqueID>100898731</NlmUniqueID><ISSNLinking>1526-8209</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="Y">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Male breast cancer</Keyword><Keyword MajorTopicYN="N">SEER</Keyword><Keyword MajorTopicYN="N">breast conservation therapy</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">trend</Keyword></KeywordList><CoiStatement>Disclosure All other authors state that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35473920</ArticleId><ArticleId IdType="doi">10.1016/j.clbc.2022.03.007</ArticleId><ArticleId IdType="pii">S1526-8209(22)00069-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35184935</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-0666</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical breast cancer</Title><ISOAbbreviation>Clin Breast Cancer</ISOAbbreviation></Journal><ArticleTitle>The use of neoadjuvant therapy increases the rate of breast conservation in men with locally advanced breast cancer.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>358</EndPage><MedlinePgn>343-358</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2022.01.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1526-8209(22)00019-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Male breast cancer (MBC) is often diagnosed at a later stage and with a more unfavorable tumor-to-breast ratio compared to women, prompting lower rates of breast conservation (BCT). We sought to assess the practice patterns of neoadjuvant therapy (NT) in MBC patients and the impact on BCT.</AbstractText><AbstractText Label="METHODS">Men with nonmetastatic, invasive breast cancer were identified from the National Cancer Database. Patients were categorized as having small (cT1/2) or locally advanced (cT3/4) tumors and by whether they received NT (which included endocrine or chemotherapy). Univariate and multivariable analyses were performed to assess patterns of NT use and rates BCT.</AbstractText><AbstractText Label="RESULTS">Of 15,151 male patients, 4.8% received NT and 21.6% underwent BCT. NT was more common among males with cT3/4 tumors than those with cT1/2 tumors (8.2 vs. 2.1%, P &lt; .001). Overall, unadjusted rates of BCT were higher for patients receiving NT in the cT3/4 subgroup (19.0 vs. 12.5%, P &lt; .001), a difference which persisted on multivariable analysis. For all patients analyzed, overall survival (OS) did not differ between males who underwent NT and those who did not (110 vs. 122 months, P&#xa0;=&#xa0;.67), but NT was associated with poorer OS in both univariate and multivariate analyses for patients with cT3/4 tumors (both P &lt; .01).</AbstractText><AbstractText Label="CONCLUSIONS">Men with invasive breast cancer have an expected low rate of BCT, but NT appears to reduce the use of mastectomy in patients with locally advanced cancers. More work is needed to understand the impacts of BCT on locoregional recurrence and disease-free and overall survival for MBC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Austin D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, Lankenau Medical Center, Wynnewood, PA. Electronic address: adwilliams5@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciocca</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lankenau Medical Center, Wynnewood, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabol</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lankenau Medical Center, Wynnewood, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carp</LastName><ForeName>Ned Z</ForeName><Initials>NZ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lankenau Medical Center, Wynnewood, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Breast Cancer</MedlineTA><NlmUniqueID>100898731</NlmUniqueID><ISSNLinking>1526-8209</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="Y">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast conserving surgery</Keyword><Keyword MajorTopicYN="N">Male breast cancer</Keyword><Keyword MajorTopicYN="N">Neoadjuvant chemotherapy</Keyword><Keyword MajorTopicYN="N">Neoadjuvant endocrine therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>21</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35184935</ArticleId><ArticleId IdType="doi">10.1016/j.clbc.2022.01.004</ArticleId><ArticleId IdType="pii">S1526-8209(22)00019-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34783719</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5628</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Nuclear medicine communications</Title><ISOAbbreviation>Nucl Med Commun</ISOAbbreviation></Journal><ArticleTitle>18F-FDG PET/CT for the evaluation of male breast cancer: a systematic review.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>128</EndPage><MedlinePgn>123-128</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MNM.0000000000001508</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the last years, some studies on the usefulness of 18F-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) for the evaluation of male breast cancer (MBC) have been produced. The aim of this review is to analyze the usefulness of 18F-FDG PET/CT and its diagnostic performances for the assessment of MBC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A wide literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was made to find relevant published articles on the role of 18F-FDG PET/CT for the evaluation of MBC. Moreover, quality assessment including the risk of bias and applicability concerns was carried out using QUADAS-2 evaluation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The comprehensive computer literature search revealed 3178 articles. On reviewing the titles and abstracts, 3170 articles were excluded because the reported data were not within the field of interest and finally eight studies were included in the review, for a total of 176 male patients. The studies considered revealed high diagnostic accuracy of 18F-FDG PET/CT for the evaluation of MBC both at staging and restaging of disease. Moreover, its added values compared to conventional imaging are starting to emerge and insight into its controversial prognostic importance is growing.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite some limitations affecting our review, 18F-FDG PET/CT seems to be a valuable tool to assess MBC. Further research studies are required to better underline the role of hybrid imaging with 18F-FDG for the evaluation of MBC, especially in comparison with female breast cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dondi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albano</LastName><ForeName>Domenico</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Giubbini</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bertagna</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nucl Med Commun</MedlineTA><NlmUniqueID>8201017</NlmUniqueID><ISSNLinking>0143-3636</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="Y">Breast Neoplasms, Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34783719</ArticleId><ArticleId IdType="doi">10.1097/MNM.0000000000001508</ArticleId><ArticleId IdType="pii">00006231-900000000-97954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Methamem M, Ghadhab I, Hidar S, Briki R. Breast cancer in men: a series of 45 cases and literature review. Pan Afr Med J 2020; 36:183.</Citation></Reference><Reference><Citation>Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004; 101:51&#x2013;57.</Citation></Reference><Reference><Citation>Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol 2021; 38:39.</Citation></Reference><Reference><Citation>Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, Schatzkin A. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008; 100:1477&#x2013;1481.</Citation></Reference><Reference><Citation>Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat 2010; 119:185&#x2013;192.</Citation></Reference><Reference><Citation>Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999; 85:629&#x2013;639.</Citation></Reference><Reference><Citation>Foerster R, Schroeder L, Foerster F, Wulff V, Schubotz B, Baaske D, Rudlowski C. Metastatic male breast cancer: a retrospective cohort analysis. Breast Care (Basel) 2014; 9:267&#x2013;271.</Citation></Reference><Reference><Citation>Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, et al. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 2018; 37:599&#x2013;614.</Citation></Reference><Reference><Citation>Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol 2018; 29:405&#x2013;417.</Citation></Reference><Reference><Citation>Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer 2013; 119:1611&#x2013;1617.</Citation></Reference><Reference><Citation>Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer 2020; 126:26&#x2013;36.</Citation></Reference><Reference><Citation>Sneige N, Holder PD, Katz RL, Fanning CV, Dekmezian RH, Shabb NS, Singletary SE. Fine-needle aspiration cytology of the male breast in a cancer center. Diagn Cytopathol 1993; 9:691&#x2013;697.</Citation></Reference><Reference><Citation>Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 2013; 24:1434&#x2013;1443.</Citation></Reference><Reference><Citation>Nofal MN, Yousef AJ. The diagnosis of male breast cancer. Neth J Med 2019; 77:356&#x2013;359.</Citation></Reference><Reference><Citation>Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155:529&#x2013;536.</Citation></Reference><Reference><Citation>Ulaner GA, Juarez J, Riedl CC, Goldman DA. 18F-FDG PET/CT for systemic staging of newly diagnosed breast cancer in men. J Nucl Med 2019; 60:472&#x2013;477.</Citation></Reference><Reference><Citation>Vadi SK, Mittal BR, Sood A, Singh G, Bal A, Parihar AS, et al. Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer. Nucl Med Commun 2019; 40:63&#x2013;72.</Citation></Reference><Reference><Citation>Piciu A, Piciu D, Polocoser N, Kovendi AA, Almasan I, Mester A, et al. Diagnostic performance of F18-FDG PET/CT in male breast cancers patients. Diagnostics (Basel) 2021; 11:119.</Citation></Reference><Reference><Citation>Sahin C, Ucpinar BA, Mut DT, Yilmaz O, Ucak R, Kaya C, Tanik C. Male breast cancer with radiological and histopathological findings. Sisli Etfal Hastan Tip Bul 2020; 54:375&#x2013;379.</Citation></Reference><Reference><Citation>Vatankulu B, I&#x15f;ik G, Kocael P, Kuyumcu S, Ilvan &#x15e;, Sa&#x11f;er S, et al. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men? Nucl Med Commun 2016; 37:1273&#x2013;1281.</Citation></Reference><Reference><Citation>Evangelista L, Bertagna F, Bertoli M, Stela T, Saladini G, Giubbini R. Diagnostic and prognostic value of 18F-FDG PET/CT in male breast cancer: results from a bicentric population. Curr Radiopharm 2016; 9:169&#x2013;177.</Citation></Reference><Reference><Citation>Groheux D, Hindi&#xe9; E, Marty M, Espi&#xe9; M, Rubello D, Vercellino L, et al. 18F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Eur J Radiol 2014; 83:1925&#x2013;1933.</Citation></Reference><Reference><Citation>Jung NY, Yoo IR, Kang BJ, Kim SH, Chae BJ, Seo YY. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients. Breast Cancer 2016; 23:141&#x2013;148.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34668577</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men.</ArticleTitle><Pagination><StartPage>302</StartPage><EndPage>309</EndPage><MedlinePgn>302-309</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.2454</ELocationID><Abstract><AbstractText>This report examined the benefits and risks of palbociclib plus endocrine therapy (ET) in men with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Palbociclib was evaluated using three independent data sources: real-world data from pharmacy and medical claims, a de-identified real-world data source derived from electronic health records (EHRs), and a global safety database. From medical and pharmacy records, 1,139 men with MBC were identified; in the first-line setting, median duration of treatment was longer with palbociclib plus ET (n&#xa0;=&#xa0;37, 8.5&#xa0;months, 95% confidence interval (CI), 4.4-13.0) than ET alone (n&#xa0;=&#xa0;214, 4.3&#xa0;months, 95% CI, 3.0-5.7) and specifically, was longer with palbociclib plus letrozole (n&#xa0;=&#xa0;26, 9.4&#xa0;months, 95% CI, 4.4-14.0) than letrozole alone (n&#xa0;=&#xa0;63, 3.0&#xa0;months, 95% CI, 1.8-4.8). In the EHR-derived database, 59 men received treatment for MBC; real-world response across all lines of therapy in the metastatic setting was reported in 4 of 12 patients (33.3%) in the palbociclib plus ET group vs. 1 of 8 (12.5%) patients in the ET group. Review of the global safety database did not identify any new safety signals in palbociclib-treated men. Real-world data indicated that men with MBC benefit from palbociclib plus ET, with a safety profile consistent with previous observations in women with MBC. Collective data on palbociclib in women and men in this report, including clinical trial data, real-world data, and a well-established risk/benefit profile, led to US approval of an expansion of the palbociclib indication to include men with MBC.</AbstractText><CopyrightInformation>&#xa9; 2021 Pfizer Inc. Clinical Pharmacology &amp; Therapeutics &#xa9; 2021 American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Albert L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Groton, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu-Kite</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pfizer Inc, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mardekian</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sindy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pfizer Inc, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Decembrino</LastName><ForeName>Jaclyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IQVIA Inc, Plymouth Meeting, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snow</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Flatiron Health, Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Flatiron Health, Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motyl Rockland</LastName><ForeName>Jillian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Flatiron Health, Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gossai</LastName><ForeName>Anala</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Flatiron Health, Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilner</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Diane D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Pfizer Inc, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang Bartlett</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oharu</LastName><ForeName>Norihiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pfizer Inc, Groton, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnell</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VanArsdale</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pfizer Inc, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Dongrui R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Pfizer Inc, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tursi</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer Srl, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LKK855W8I</RegistryNumber><NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance></Chemical><Chemical><RegistryNumber>G9ZF61LE7G</RegistryNumber><NameOfSubstance UI="C500026">palbociclib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000067575" MajorTopicYN="N">Administrative Claims, Healthcare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="N">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>8</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34668577</ArticleId><ArticleId IdType="doi">10.1002/cpt.2454</ArticleId></ArticleIdList><ReferenceList><Title>&#xa0;</Title><Reference><Citation>American Cancer Society. Key Statistics for Breast Cancer in Men &lt;https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html&gt; (2020). Accessed December 1, 2020.</Citation></Reference><Reference><Citation>Giordano, S.H. Breast cancer in men. N. Engl. J. Med. 378, 2311-2320 (2018).</Citation></Reference><Reference><Citation>Chavez-Macgregor, M., Clarke, C.A., Lichtensztajn, D., Hortobagyi, G.N. &amp; Giordano, S.H. Male breast cancer according to tumor subtype and race: a population-based study. Cancer 119, 1611-1617 (2013).</Citation></Reference><Reference><Citation>Fentiman, I.S., Fourquet, A. &amp; Hortobagyi, G.N. Male breast cancer. Lancet 367, 595-604 (2006).</Citation></Reference><Reference><Citation>Hassett, M.J. et al. Management of male breast cancer: ASCO guideline. J. Clin. Oncol. 38, 1849-1863 (2020).</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&#xae;) Breast Cancer Version 1.2019 &lt;https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf&gt; (2019). Accessed December 1, 2020.</Citation></Reference><Reference><Citation>Verzenio&#x2122; (abemaciclib). Full Prescribing Information (Lilly USA, LLC, Indianapolis, IN, 2020).</Citation></Reference><Reference><Citation>IBRANCE&#xae; capsules (palbociclib). Full Prescribing Information (Pfizer Inc, New York, NY, 2019).</Citation></Reference><Reference><Citation>Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425-439 (2016).</Citation></Reference><Reference><Citation>Finn, R.S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25-35 (2015).</Citation></Reference><Reference><Citation>Finn, R.S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925-1936 (2016).</Citation></Reference><Reference><Citation>Turner, N.C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209-219 (2015).</Citation></Reference><Reference><Citation>Rugo, H.S. et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res. Treat. 174, 719-729 (2019).</Citation></Reference><Reference><Citation>Cristofanilli, M. et al. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Eur. J. Cancer 104, 21-31 (2018).</Citation></Reference><Reference><Citation>Brufsky, A., Liu, X., Li, B., McRoy, L. &amp; Layman, R.M. Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol. 16, 601-611 (2021).</Citation></Reference><Reference><Citation>DeMichele, A. et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 23, 37 (2021).</Citation></Reference><Reference><Citation>Bui, T.B.V., Burgers, D.M., Agterof, M.J. &amp; van de Garde, E.M. Real-world effectiveness of palbociclib versus clinical trial results in patients with advanced/metastatic breast cancer that progressed on previous endocrine therapy. Breast Cancer (Auckl.) 13, 1-6 (2019).</Citation></Reference><Reference><Citation>VanArsdale, T., Boshoff, C., Arndt, K.T. &amp; Abraham, R.T. Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin. Cancer Res. 21, 2905-2910 (2015).</Citation></Reference><Reference><Citation>Sorscher, S. A first case of male breast cancer responding to combined aromatase inhibitor/palbociclib therapy. Int. J. Cancer Clin. Res. 3, 1-2 (2016).</Citation></Reference><Reference><Citation>Schwartz, G.K. et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br. J. Cancer 104, 1862-1868 (2011).</Citation></Reference><Reference><Citation>Flaherty, K.T. et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin. Cancer Res. 18, 568-576 (2012).</Citation></Reference><Reference><Citation>Beaver, J.A. et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin. Cancer Res. 21, 4760-4766 (2015).</Citation></Reference><Reference><Citation>US Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2018 Through 2022 &lt;https://www.fda.gov/media/99140/download&gt;. Accessed December 1, 2020.</Citation></Reference><Reference><Citation>Center for Drug Evaluation and Research. Guidance for Industry: Male Breast Cancer: Developing Drugs for Treatment &lt;https://www.fda.gov/media/130061/download&gt; (2019). Accessed December 1, 2020.</Citation></Reference><Reference><Citation>Di&#xe9;ras, V. et al. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer. J. Natl. Cancer Inst. 111, 419-430 (2019).</Citation></Reference><Reference><Citation>Leonard, J.P. et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119, 4597-4607 (2012).</Citation></Reference><Reference><Citation>Verzenio&#x2122; (abemaciclib). Full Prescribing Information (Lilly USA, LLC, Indianapolis, IN, 2019).</Citation></Reference><Reference><Citation>Kisqali&#xae; (ribociclib). Full Prescribing Information (Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2019).</Citation></Reference><Reference><Citation>DeLaurentiis, M. et al. Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: preliminary results from the phase 3b CompLEEment-1 trial [abstract]. J. Clin. Oncol. 36(suppl 5), 1056 (2018).</Citation></Reference><Reference><Citation>Huang Bartlett, C. et al. Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS One 15, e0227256 (2020).</Citation></Reference><Reference><Citation>Wedam, S. et al. FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin. Cancer Res. 26, 1208-1212 (2019).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34550927</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-4242</ISSN><JournalIssue CitedMedium="Internet"><Volume>148</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Plastic and reconstructive surgery</Title><ISOAbbreviation>Plast Reconstr Surg</ISOAbbreviation></Journal><ArticleTitle>Technical Refinement in Three-Dimensional Nipple-Areola Complex Tattooing of the Reconstructed Breast.</ArticleTitle><Pagination><StartPage>737</StartPage><EndPage>746</EndPage><MedlinePgn>737-746</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PRS.0000000000008390</ELocationID><Abstract><AbstractText>Three-dimensional nipple-areola complex tattooing has previously been described as an alternative to surgical reconstruction using local flaps and grafts. This technique offers patients an option that can achieve aesthetically pleasing results without a donor site, changes in projection over time, or additional scarring. Plastic surgeons may be limited in their ability to create a realistic-appearing nipple-areola complex because of limited experience with basic tattooing techniques and unfamiliarity with the artistic principles of light and shadow required to create depth on a two-dimensional surface. Consistent results can be achieved with attention to the technical pearls discussed in this article.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 by the American Society of Plastic Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruffolo</LastName><ForeName>Alexis M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the Institute for Plastic Surgery, Southern Illinois University School of Medicine; and Newage Tattoo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>From the Institute for Plastic Surgery, Southern Illinois University School of Medicine; and Newage Tattoo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daugherty</LastName><ForeName>Timothy H F</ForeName><Initials>THF</Initials><AffiliationInfo><Affiliation>From the Institute for Plastic Surgery, Southern Illinois University School of Medicine; and Newage Tattoo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Springfield, Ill.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>From the Institute for Plastic Surgery, Southern Illinois University School of Medicine; and Newage Tattoo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommer</LastName><ForeName>Nicole Z</ForeName><Initials>NZ</Initials><AffiliationInfo><Affiliation>From the Institute for Plastic Surgery, Southern Illinois University School of Medicine; and Newage Tattoo.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Plast Reconstr Surg</MedlineTA><NlmUniqueID>1306050</NlmUniqueID><ISSNLinking>0032-1052</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="N">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019074" MajorTopicYN="N">Epigastric Arteries</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004954" MajorTopicYN="N">Esthetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016462" MajorTopicYN="N">Mammaplasty</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009558" MajorTopicYN="N">Nipples</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061525" MajorTopicYN="N">Perforator Flap</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013653" MajorTopicYN="Y">Tattooing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34550927</ArticleId><ArticleId IdType="doi">10.1097/PRS.0000000000008390</ArticleId><ArticleId IdType="pii">00006534-202110000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smallman A, Crittenden T, MiinYip J, Dean NR. Does nipple-areolar tattooing matter in breast reconstruction? A cohort study using the BREAST-Q. JPRAS Open 2018;16:61&#x2013;68.</Citation></Reference><Reference><Citation>Bykowski MR, Emelife PI, Emelife NN, Chen W, Panetta NJ, de la Cruz C. Nipple&#x2013;areola complex reconstruction improves psychosocial and sexual well-being in women treated for breast cancer. J Plast Reconstr Aesthet Surg. 2017;70:209&#x2013;214.</Citation></Reference><Reference><Citation>Wellisch DK, Schain WS, Noone RB, Little JW III. The psychological contribution of nipple addition in breast reconstruction. Plast Reconstr Surg. 1987;80:699&#x2013;704.</Citation></Reference><Reference><Citation>Winocour S, Saksena A, Oh C, et al. A systematic review of comparison of autologous, allogeneic, and synthetic augmentation grafts in nipple reconstruction. Plast Reconstr Surg. 2016;137:14e&#x2013;23e.</Citation></Reference><Reference><Citation>Jabor MA, Shayani P, Collins DR Jr, Karas T, Cohen BE. Nipple-areola reconstruction: Satisfaction and clinical determinants. Plast Reconstr Surg. 2002;110:457&#x2013;463; discussion 464&#x2013;465.</Citation></Reference><Reference><Citation>Azouz S, Swanson M, Omarkhil M, Rebecca A. A nipple-areola stencil for three-dimensional tattooing: Nipple by number. Plast Reconstr Surg. 2020;145:38&#x2013;42.</Citation></Reference><Reference><Citation>Becker H. Nipple-areola reconstruction using intradermal tattoo. Plast Reconstr Surg. 1988;81:450&#x2013;453.</Citation></Reference><Reference><Citation>Spear SL, Arias J. Long-term experience with nipple-areola tattooing. Ann Plast Surg. 1995;35:232&#x2013;236.</Citation></Reference><Reference><Citation>Goh SC, Martin NA, Pandya AN, Cutress RI. Patient satisfaction following nipple-areolar complex reconstruction and tattooing. J Plast Reconstr Aesthet Surg. 2011;64:360&#x2013;363.</Citation></Reference><Reference><Citation>El-Ali K, Dalal M, Kat CC. Tattooing of the nipple-areola complex: Review of outcome in 40 patients. J Plast Reconstr Aesthet Surg. 2006;59:1052&#x2013;1057.</Citation></Reference><Reference><Citation>Cha HG, Kwon JG, Kim EK, Lee HJ. Tattoo-only nipple-areola complex reconstruction: Another option for plastic surgeons. J Plast Reconstr Aesthet Surg. 2020;73:696&#x2013;702.</Citation></Reference><Reference><Citation>Glassy CM, Glassy MS, Aldasouqi S. Tattooing: Medical uses and problems. Cleve Clin J Med. 2012;79:761&#x2013;770.</Citation></Reference><Reference><Citation>Halvorson EG, Cormican M, West ME, Myers V. Three-dimensional nipple-areola tattooing: A new technique with superior results. Plast Reconstr Surg. 2014;133:1073&#x2013;1075.</Citation></Reference><Reference><Citation>Sanuki J, Fukuma E, Uchida Y. Morphologic study of nipple-areola complex in 600 breasts. Aesthetic Plast Surg. 2009;33:295&#x2013;297.</Citation></Reference><Reference><Citation>Tanini S, Lo Russo G. Shape, position and dimension of the nipple areola complex in the ideal male chest: A quick and simple operating room technique. Aesthet Plast Surg. 2018;42:951&#x2013;957.</Citation></Reference><Reference><Citation>Yue D, Cooper LRL, Kerstein R, Charman SC, Kang NV. Defining normal parameters for the male nipple-areola complex: A prospective observational study and recommendations for placement on the chest wall. Aesthet Surg J. 2018;38:742&#x2013;748.</Citation></Reference><Reference><Citation>Beckenstein MS, Windle BH, Stroup RT Jr. Anatomical parameters for nipple position and areolar diameter in males. Ann Plast Surg. 1996;36:33&#x2013;36.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34403063</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1880-4233</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Breast cancer (Tokyo, Japan)</Title><ISOAbbreviation>Breast Cancer</ISOAbbreviation></Journal><ArticleTitle>High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.</ArticleTitle><Pagination><StartPage>103</StartPage><EndPage>113</EndPage><MedlinePgn>103-113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12282-021-01286-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Though BRCA1 mutation is the most susceptible factor of breast cancer, its prognostic value is disputable. Here in this study, we use a novel method which based on whole-genome analysis to evaluate the chromosome instability (CIN) value and identified the potential relationship between CIN and prognosis of breast cancer patients with germline-BRCA1 mutation.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Sanger sequencing or a 98-gene panel sequencing assay was used to screen for BRCA1 germline small mutations in 1151 breast cancer patients with high-risk factors. MLPA assay was employed to screen BRCA1 large genomic rearrangements in familial breast cancer patients with BRCA1 negative for small mutations. Thirty-two samples with unique BRCA1 germline mutation patterns were further subjected to CIN evaluation by LPWGS (low-pass whole-genome sequencing) technology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Firstly, 113 patients with germline BRCA1 mutations were screened from the cohort. Further CIN analysis by the LPWGS assay indicated that CIN was independent from the mutation location or type of BRCA1. Patients with high CIN status had shorter disease-free survival rates (DFS) (HR&#x2009;=&#x2009;6.54, 95% CI 1.30-32.98, P&#x2009;=&#x2009;0.034). The TP53 copy loss was also characterized by LPWGS assay. The rates of TP53 copy loss in CIN high and CIN low groups were 85.71% (12/14) and 16.67% (3/18), respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CIN-high is a prognostic factor correlated with shorter DFS and was independent with the germline BRCA1 mutation pattern. Higher CIN values were significantly correlated with TP53 copy loss in breast cancer patients with germline BRCA1 mutation. Our results revealed a reliable molecular parameter for distinguishing patients with poor prognosis from the BRCA1-mutated breast cancer patients.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhu</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pan</LastName><ForeName>Jia-Ni</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zhejiang Chinese Medical University, Hangzhou, 310053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Ziliang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Prophet Genomics Inc, San Jose, CA, 95131, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Suzhou Hongyuan Biotech Inc, Biobay, Suzhou, 215123, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Wei-Wu</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao-Jia</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Wen-Ming</ForeName><Initials>WM</Initials><Identifier Source="ORCID">0000-0002-5644-3156</Identifier><AffiliationInfo><Affiliation>Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China. caowm@zjcc.org.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China. caowm@zjcc.org.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Breast Cancer</MedlineTA><NlmUniqueID>100888201</NlmUniqueID><ISSNLinking>1340-6868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="N">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043171" MajorTopicYN="Y">Chromosomal Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="Y">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018095" MajorTopicYN="Y">Germ-Line Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BRCA1</Keyword><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">CIN</Keyword><Keyword MajorTopicYN="N">LPWGS</Keyword><Keyword MajorTopicYN="N">TP53</Keyword></KeywordList><CoiStatement>All the authors declare that they have no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34403063</ArticleId><ArticleId IdType="pmc">PMC8732803</ArticleId><ArticleId IdType="doi">10.1007/s12282-021-01286-1</ArticleId><ArticleId IdType="pii">10.1007/s12282-021-01286-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharma P, et al. BRCA1 insufficiency is predictive of superior survival in patients with triple negative breast cancer treated with platinum-based chemotherapy. 2012.</Citation></Reference><Reference><Citation>Sharma P, et al. The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res. 2014;3:1&#x2013;11. doi: 10.7243/2049-7962-3-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.7243/2049-7962-3-2</ArticleId><ArticleId IdType="pmc">PMC4147783</ArticleId><ArticleId IdType="pubmed">25177489</ArticleId></ArticleIdList></Reference><Reference><Citation>Copson ER, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169&#x2013;180. doi: 10.1016/S1470-2045(17)30891-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(17)30891-4</ArticleId><ArticleId IdType="pmc">PMC5805863</ArticleId><ArticleId IdType="pubmed">29337092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang GT, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int J Cancer. 2017;141:129&#x2013;142. doi: 10.1002/ijc.30692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.30692</ArticleId><ArticleId IdType="pubmed">28294317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res. 2017;23:6113&#x2013;6119. doi: 10.1158/1078-0432.CCR-16-3227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3227</ArticleId><ArticleId IdType="pubmed">28724667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban S, et al. Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay. Mutat Res. 2001;474:15&#x2013;23. doi: 10.1016/S0027-5107(00)00152-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0027-5107(00)00152-4</ArticleId><ArticleId IdType="pubmed">11239959</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigorova M, Staines JM, Ozdag H, Caldas C, Edwards PA. Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1. Cytogenet Genome Res. 2004;104:333&#x2013;340. doi: 10.1159/000077512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000077512</ArticleId><ArticleId IdType="pubmed">15162061</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell RA, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013;494:492&#x2013;496. doi: 10.1038/nature11935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11935</ArticleId><ArticleId IdType="pmc">PMC4636055</ArticleId><ArticleId IdType="pubmed">23446422</ArticleId></ArticleIdList></Reference><Reference><Citation>Knouse KA, Davoli T, Elledge SJ, Amon A. Aneuploidy in cancer: seq-ing answers to old questions. Annu Rev Cancer Biol. 2017;1:335&#x2013;354. doi: 10.1146/annurev-cancerbio-042616-072231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cancerbio-042616-072231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61&#x2013;70. doi: 10.1038/nature11412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11412</ArticleId><ArticleId IdType="pmc">PMC3465532</ArticleId><ArticleId IdType="pubmed">23000897</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043&#x2013;1048. doi: 10.1038/ng1861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1861</ArticleId><ArticleId IdType="pubmed">16921376</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepage CC, Morden CR, Palmer MCL, Nachtigal MW, McManus KJ. Detecting Chromosome Instability in Cancer: Approaches to Resolve Cell-to-Cell Heterogeneity. Cancers (Basel). 2019; 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6406658</ArticleId><ArticleId IdType="pubmed">30781398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, et al. Analysis of centromere signal patterns in breast cancer cells with chromosomal instability using image cytometry combined with centromere fluorescence in situ hybridization. Cytometry A. 2014;85:809&#x2013;816. doi: 10.1002/cyto.a.22502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22502</ArticleId><ArticleId IdType="pubmed">25044720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K, et al. Centromere 17 copy number gain reflects chromosomal instability in breast cancer. Sci Rep. 2019;9:17968. doi: 10.1038/s41598-019-54471-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-54471-w</ArticleId><ArticleId IdType="pmc">PMC6884473</ArticleId><ArticleId IdType="pubmed">31784614</ArticleId></ArticleIdList></Reference><Reference><Citation>Salgueiro L, et al. Acquisition of chromosome instability is a mechanism to evade oncogene addiction. EMBO Mol Med. 2020;12:e10941. doi: 10.15252/emmm.201910941.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201910941</ArticleId><ArticleId IdType="pmc">PMC7059010</ArticleId><ArticleId IdType="pubmed">32030896</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Z, et al. Low-pass whole-genome sequencing in clinical cytogenetics: a validated approach. Genet Med. 2016;18:940&#x2013;948. doi: 10.1038/gim.2015.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.199</ArticleId><ArticleId IdType="pubmed">26820068</ArticleId></ArticleIdList></Reference><Reference><Citation>CORRIGENDUM: Low-pass whole-genome sequencing in clinical cytogenetics: a validated approach. Genet Med. 2017; 19, 129.</Citation><ArticleIdList><ArticleId IdType="pubmed">28072407</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, et al. Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort. Clin Cancer Res. 2019;25:2254&#x2013;2263. doi: 10.1158/1078-0432.CCR-18-1593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1593</ArticleId><ArticleId IdType="pubmed">30617129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, et al. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse. Breast Cancer Res Treat. 2019;178:63&#x2013;73. doi: 10.1007/s10549-019-05375-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-019-05375-w</ArticleId><ArticleId IdType="pubmed">31364001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhen O, et al. Comparison of circulating tumour DNA and extracellular vesicle DNA by low-pass whole-genome sequencing reveals molecular drivers of disease in a breast cancer patient. Biomedicines, 2020; 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7823926</ArticleId><ArticleId IdType="pubmed">33375577</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Gou Q, Wang Q, Zhong X, Zheng H. The role of BRCA status on prognosis in patients with triple-negative breast cancer. Oncotarget. 2017;8:87151&#x2013;87162. doi: 10.18632/oncotarget.19895.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.19895</ArticleId><ArticleId IdType="pmc">PMC5675622</ArticleId><ArticleId IdType="pubmed">29152070</ArticleId></ArticleIdList></Reference><Reference><Citation>Staaf J, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25:1526&#x2013;1533. doi: 10.1038/s41591-019-0582-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0582-4</ArticleId><ArticleId IdType="pmc">PMC6859071</ArticleId><ArticleId IdType="pubmed">31570822</ArticleId></ArticleIdList></Reference><Reference><Citation>Huzarski T, et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. 2013;31:3191&#x2013;3196. doi: 10.1200/JCO.2012.45.3571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2012.45.3571</ArticleId><ArticleId IdType="pubmed">23940229</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogoda K, et al. Effects of BRCA germline mutations on triple-negative breast cancer prognosis. J Oncol. 2020;2020:8545643. doi: 10.1155/2020/8545643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8545643</ArticleId><ArticleId IdType="pmc">PMC7165358</ArticleId><ArticleId IdType="pubmed">32322271</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer. Br J Cancer. 2008;99:513&#x2013;519. doi: 10.1038/sj.bjc.6604479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6604479</ArticleId><ArticleId IdType="pmc">PMC2527807</ArticleId><ArticleId IdType="pubmed">18665192</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AB, Schumacher B. p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med, 2016; 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852800</ArticleId><ArticleId IdType="pubmed">27048304</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenblatt MS, Grollman AP, Harris CC. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res. 1996;56:2130&#x2013;2136.</Citation><ArticleIdList><ArticleId IdType="pubmed">8616861</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem. 2012;113:433&#x2013;439. doi: 10.1002/jcb.23400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.23400</ArticleId><ArticleId IdType="pmc">PMC4407809</ArticleId><ArticleId IdType="pubmed">22006292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 1997;11:1226&#x2013;1241. doi: 10.1101/gad.11.10.1226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.11.10.1226</ArticleId><ArticleId IdType="pubmed">9171368</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen SX, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene. 1998;17:3115&#x2013;3124. doi: 10.1038/sj.onc.1202243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1202243</ArticleId><ArticleId IdType="pubmed">9872327</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Li W, Kim S, Brodie SG, Deng CX. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev. 2003;17:201&#x2013;213. doi: 10.1101/gad.1050003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1050003</ArticleId><ArticleId IdType="pmc">PMC195980</ArticleId><ArticleId IdType="pubmed">12533509</ArticleId></ArticleIdList></Reference><Reference><Citation>Linger RJ, Kruk PA. BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications. FEBS J. 2010;277:3086&#x2013;3096. doi: 10.1111/j.1742-4658.2010.07735.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2010.07735.x</ArticleId><ArticleId IdType="pubmed">20608970</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebbeck TR, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313:1347&#x2013;1361. doi: 10.1001/jama.2014.5985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.5985</ArticleId><ArticleId IdType="pmc">PMC4537700</ArticleId><ArticleId IdType="pubmed">25849179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
